Key result
Irbesartan reduced left ventricular mass index significantly more than atenolol (26 vs 14 g/m2; P=0.024) in patients with hypertension and left ventricular hypertrophy over 48 weeks.
Why the study?
Does irbesartan reduce left ventricular mass more than atenolol in hypertensive patients with left ventricular hypertrophy?
Population
115 hypertensive men and women with left ventricular hypertrophy
Comparison
Irbesartan 150 mg once daily for 48 weeks vs Atenolol 50 mg once daily for 48 weeks
Design
RCT, randomized, double-blind
Follow-up
48 weeks
Authors
Loading...
Supports preferring irbesartan over atenolol for LVH regression in hypertension; confirms ARB benefit beyond BP reduction.
RCT (n=115)
Double-blind
randomized
Does irbesartan reduce left ventricular mass more than atenolol in hypertensive patients with left ventricular hypertrophy?
Absolute Event Rate: 26% vs 14%
p-value: p=0.024
In hypertensive patients with left ventricular hypertrophy, irbesartan provides greater regression of left ventricular mass compared to atenolol, despite similar blood pressure reductions.
Malmqvist et al. (2001) conducted an RCT in hypertension with left ventricular hypertrophy (n=115). Irbesartan vs. Atenolol 50 mg q.d. was evaluated on reduction in left ventricular mass index at week 48 (p=0.024). Irbesartan reduced left ventricular mass index significantly more than atenolol (26 vs 14 g/m2; P=0.024) in patients with hypertension and left ventricular hypertrophy over 48 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: